Baseline patient and disease characteristics
| Assessment | Infliximab | Etanercept |
|---|---|---|
| CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drug; SF-36, short form-36 health survey questionnaire; SJC, swollen joint count; TJC, tender joint count. | ||
| Number | 13 | 14 |
| Women, % | 84.6 | 100 |
| Mean (SD) age (years) | 45.1 (13.5) | 52.2 (14.5) |
| Disease characteristics | ||
| Duration of disease | ||
| Mean (SD) (years) | 9.6 (11.3) | 12.1 (10.7) |
| Median (years) | 4.0 | 8.7 |
| Range (years) | 0.5–34.8 | 1.7–37.0 |
| Mean (SD) SJC | 20.7 (9.9) | 20.1 (6.9) |
| Median (years) | 18.0 | 19.5 |
| Range (years) | 8.0–44.0 | 11.0–34.0 |
| Mean (SD) TJC | 31.4 (17.7) | 25.6 (14.5) |
| Median (years) | 24.7 | 21.0 |
| Range (years) | 12.0–66.0 | 9.0–56.0 |
| CRP (mg/l) | ||
| Median | 2.3 | 5.9 |
| Range | 0.4–50.3 | 1.2–44.9 |
| ESR (mm/h) | ||
| Median | 26 | 31 |
| Range | 4–78 | 7–74 |
| Concomitant medications | ||
| Prednisone therapy, % | 30.8 | 28.6 |
| NSAID therapy, % | 69.2 | 78.6 |
| DMARD therapy, % | 100 | 100 |
| Clinical assessment | ||
| Health Assessment | ||
| Questionnaire score | ||
| Mean (SD) | 1.4 (0.7) | 1.5 (0.6) |
| Median (IQR) | 1.4 (1.0–1.9) | 1.6 (1.1–1.9) |
| DAS28 score | ||
| Mean (SD) | 6.2 (1.2) | 6.5 (0.8) |
| Median (IQR) | 5.9 (4.2–7.7) | 6.5 (5.2–7.6) |
| SF-36 score | ||
| Physical component summary | ||
| Mean (SD) | 32.9 (7.0) | 28.6 (7.4) |
| Median (IQR) | 30.4 (29.2–39.8) | 27.7 (24.9–31.9) |
| Mental component summary | ||
| Mean (SD) | 43.8 (11.2) | 46.2 (9.9) |
| Median (IQR) | 39.3 (36.9–54.3) | 45.3 (37.1–53.4) |
| Beck depression inventory | ||
| Mean (SD) | 12.5 (9.5) | 11.6 (9.8) |
| Median (IQR) | 8.0 (5.0–23.0) | 9.0 (5.0–14.0) |
| Sharp score (van der Heijde modified) (hands and feet) | ||
| Mean (SD) | 32.5 (39.7) | 47.5 (50.8) |
| Median (IQR) | 20.5 (15.0–38.5) | 26.6 (8.5–80.5) |